Lectenz Bio Signs Distribution Agreement with 2B Scientific
Lectenz Bio has recently signed a distribution agreement with 2B Scientific, a life sciences distributor. This agreement will allow 2B Scientific...
Read moreLectenz Bio has recently signed a distribution agreement with 2B Scientific, a life sciences distributor. This agreement will allow 2B Scientific...
Read moreLectenz Bio has recently signed a distribution agreement with Funakoshi Co., Ltd., a Japanese life science distributor. This agreement will allow...
Read moreWe’d like to take a brief moment to update you on our company plans as the COVID-19 situation progresses. At Lectenz Bio, our employees’ safety is...
Read moreThe NIH National Institute of General Medical Sciences (NIGMS) awards Lectenz Bio an SBIR Phase I to develop heparan sulfate...
Read moreThe NIH National Institute of General Medical Sciences (NIGMS) awards Lectenz Bio an SBIR Phase I to develop fucose...
Read moreLectenz Bio attended the ACS Fall 2019 National Meeting, where Dr. Matthew Saunders presented Glycosense™: Simple alternative to existing...
Read moreLectenz Bio founders, Lori Yang and Rob Woods are highlighted in an ASBMB featured story, Setting Sail in a Startup: How academic entrepreneurs...
Read moreChristian Gerner-Smidt and Lori Yang attended the 20th European Carbohydrate Symposium in Leiden, The Netherlands. Dr. Yang gave a lecture...
Read moreLectenz Bio completed the Spring 2019 SBIR NIH I-Corps cohort in Bethesda Maryland! During the 8-week program, our team – Sean Wu (C-Level...
Read moreDr. Lori Yang and Dr. Joshua Renfroe presented posters at the 34th Congress of the International Society for Advancement of Cytometry in...
Read moreDr. Sean Wu and Dr. Joshua Renfroe attend the 13th Jenner Glycobiology and Medicine Symposium in Cambridge, MA. Learn more about the Jenner...
Read moreLectenz Bio has been accepted to the National Institute of Health (NIH) I-Corps program for SBIR phase I awardees. The goal of the program is to...
Read more